BFM
BBIO icon

Boothbay Fund Management’s BridgeBio Pharma BBIO Stock Holding History

Boothbay Fund Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,000
Closed -$516K – 1733
2023
Q2 		$516K Buy
+30,000
New +$451K 0.01% 1084
2022
Q1 		– Sell
-210,800
Closed -$3.52M – 2271
2021
Q4 		$3.52M Buy
+210,800
New +$8.92M 0.08% 295

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Boothbay Fund Management's BBIO Position: Q2 2026 in Review

Boothbay Fund Management reduced its BridgeBio Pharma (BBIO) stake by 67% in Q2 2026, selling an estimated $2.19M and leaving 15,713 shares worth $1.17M. The position accounts for 0.02% of the portfolio, ranked #1000.

Boothbay Fund Management first reported a position in BBIO in Q4 2021 and has held it in 13 quarters since. The position peaked at $4.21M in Q4 2023. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Boothbay Fund Management held 15,713 shares of BridgeBio Pharma worth $1.17M as of Q2 2026.
  • Boothbay Fund Management sold 31,268 BridgeBio Pharma shares in Q2 2026, an estimated $2.19M.
  • BridgeBio Pharma made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #1000 holding.
  • Boothbay Fund Management first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 13 quarters since.
  • Boothbay Fund Management's BridgeBio Pharma position peaked at $4.21M in Q4 2023.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.